Pacira BioSciences, Inc. (PCRX) Stock Forecast
PCRX analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.22 / 5 from 9 analysts
- Price target
- $33.57 average of analyst targets
- Upside to target
- −7.6% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.47
- 52-week range
- $19.16 – $36.40
PCRX analyst ratings
9 analystsNumber of analysts at each rating.
PCRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PCRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.73 | $0.52 | $0.82 | $0.70 | +4.5% | 9 |
| Current fiscal year (2026) | $2.90 | $2.72 | $2.99 | $2.65 | +9.3% | 9 |
| Next fiscal year (2027) | $3.46 | $3.05 | $3.94 | $2.90 | +19.4% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PCRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $182.9M | $176.9M | $187.4M | +1.9% | 8 |
| Current fiscal year (2026) | $754.3M | $747.8M | $759.4M | +3.8% | 8 |
| Next fiscal year (2027) | $790.0M | $761.8M | $812.7M | +4.7% | 8 |
PCRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PCRX revenue: reported and forecast
PCRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.76 | $0.77 | $0.72 | $0.73 | $0.73 | −3.6% | 1 up · 0 down |
| Current fiscal year (2026) | $2.88 | $2.95 | $2.89 | $2.89 | $2.90 | +0.7% | 1 up · 0 down |
| Next fiscal year (2027) | $3.65 | $3.49 | $3.44 | $3.44 | $3.46 | −5.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PCRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PCRX beat in 10 of 12.
What analysts expect from PCRX
9 analysts cover Pacira BioSciences; their consensus rating is hold (3.22 on a 1–5 scale, where 5 is a strong buy). The average price target is $33.57, 7.6% below the latest close of $36.34. Analysts expect earnings of $2.90 per share for 2026, +9.3% from a year earlier. For 2027 the average estimate is $3.46 per share on revenue of $790.0 million. Pacira BioSciences beat the EPS estimate in 10 of the last 12 quarters.
Related: PCRX income statement, PCRX key metrics, PCRX chart. See the PCRX stock overview for the latest quote and news.
PCRX forecast FAQ
What is Pacira BioSciences's price target?
The average analyst price target for Pacira BioSciences is $33.57, 7.6% below the latest close of $36.34.
Is Pacira BioSciences a buy, hold or sell?
Of 9 analysts covering Pacira BioSciences, 1 rate it a strong buy, 0 a buy, 8 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Pacira BioSciences's EPS forecast?
Analysts forecast $2.90 per share for 2026 (range $2.72 to $2.99); for 2027 the estimate is $3.46.
What is Pacira BioSciences's revenue forecast?
The average revenue estimate for 2026 is $754.3 million, growth of 3.8%; for 2027 it is $790.0 million.
When does Pacira BioSciences report earnings?
Pacira BioSciences is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $0.47.
Does Pacira BioSciences usually beat earnings estimates?
Pacira BioSciences reported EPS at or above the analyst estimate in 10 of the last 12 quarters.